Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf173 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Amélie Ciernik und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland. Hauptthemen laut MEDLINE: Melanoma, Nivolumab, Ipilimumab, Uveal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Uveal melanoma (UM) is the most common primary ocular malignancy with a high rate of metastases. While immune checkpoint inhibitors (ICIs), including ipilimumab and nivolumab (ipi + nivo), have shown efficacy in metastatic cutaneous melanoma, their success in metastatic UM (MUM) remains limited. This study evaluates toxicity and outcomes of ipi + nivo in the largest, multicenter MUM cohort.
Methods
We analyzed 131 MUM patients treated with ipi + nivo from 2016 to 2024 across 5 international centers. Rates of toxicity, response, and survival outcomes were assessed.
Results
Among 131 patients, 37.4% of patients received 4 cycles of ipi + nivo. The most common reason for ipi + nivo discontinuation (31.3%) was toxicity. Of all treated patients, 80.2% experienced immune-related adverse events (irAEs). The overall response rate (ORR) was 16.4%, and the disease control rate (DCR) was 43.4%. Progression-free survival (PFS) was three months, and the median overall survival (OS) was 18 months. Patients receiving ipi + nivo as second-line therapy had lower ORR compared to patients who received ipi + nivo as first-line therapy (P = .04). Patients with exclusively extrahepatic metastases had a better ORR and OS compared to those with hepatic or mixed metastases (P = .02, P = .02, respectively). 20.6% of patients developed eosinophilia during treatment, which was associated with improved median OS (24 months vs 15 months, P = .02).
Conclusions
Ipi + nivo shows moderate efficacy and clinically relevant toxicities in patients with MUM. Eosinophilia is a potential prognostic biomarker, that merits further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland.
- Medical Faculty, University of Zurich, Zurich 8032, Switzerland.
- BIFOLD, Technische Universität Berlin, Berlin 10587, Germany.
- Hector Fellow Academy, Karlsruhe, Berlin 76131, Germany.
- Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University (LMU) Munich, Munich 80337, Germany.
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston 02114, United States.
ORCID-Profile: Amélie Ciernik, Lucie Heinzerling, Egle Ramelyte
Zitieren
APA
Ciernik, A., Ciernik, L., Bonczkowitz, P., Morak, M., Heinzerling, L., Bennaceur, Y., Lawless, A., Sullivan, R., Kött, J., Gebhardt, C., Carter, T. J., Nathan, P., Tschopp, S., Dummer, R., & Ramelyte, E. (2025). Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma. The Oncologist. https://doi.org/10.1093/oncolo/oyaf173
Vancouver
Ciernik A, Ciernik L, Bonczkowitz P, Morak M, Heinzerling L, Bennaceur Y, et al. Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma. The Oncologist. 2025. doi:10.1093/oncolo/oyaf173
BibTeX
@article{Ciernik2025,
author = {Ciernik, Amélie and Ciernik, Laure and Bonczkowitz, Peter and Morak, Monika and Heinzerling, Lucie and Bennaceur, Yacine and Lawless, Aleigha and Sullivan, Ryan and Kött, Julian and Gebhardt, Christoffer and Carter, Thomas J and Nathan, Paul and Tschopp, Sophie and Dummer, Reinhard and Ramelyte, Egle},
title = {Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf173}
}
EUVIMED